Drug Trial Radar · NCT05603039
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
80
Planned (sponsor's estimate)
Start
Jul 1, 2021
Primary completion
Dec 30, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular carcinoma.
Conditions
- Advanced Liver Cancer
Interventions
QL1706Drug
5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
QL1604Drug
200mg#D1#Q3W IV
BevacizumabDrug
15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective remission rate (ORR)Time frame: up to 1year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.